UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Investors use market indices for benchmarking, asset allocation, and risk management, enabling efficient, cost-effective exposure to markets.
27,738 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A single press conference can tilt markets. This guide breaks down what happened after Powell's remarks, what it coul...
As interest rates climb, even active managers recalibrate risk. Advocacy Wealth Management recently trimmed a major P...
As SpaceX prepares to enter the public markets, investors face a mix of hype and risk. This guide unpacks what histor...
When headlines shift at the Fed, markets tend to move fast. This piece breaks down how Warsh becoming Fed Chair could...
SpaceX plans a June NASDAQ debut with a tight float and a 366-day lock-up for founders. Analysts warn index funds cou...
SpaceX's market debut ignited a wave of aggressive bets on disruptive ideas. Investors pile into moonshot bets as opt...
Investors are re-evaluating JEPI after peers showed stronger upside. This report breaks down the real costs behind JE...
SpaceX is set to join the Nasdaq-100 on Tuesday, heightening the volatility gap with the S&P 500. The nasdaq-100 been...
Is a $5 trillion Apple valuation possible by the end of 2026? This guide weighs the growth engines, risks, and action...
Global X's RYLD, a Russell 2000 covered-call ETF, underperforms uncapped peers this year as small-cap volatility ease...
Facing a slide in Micron's stock, investors wonder: why is micron stock still falling? This guide breaks down the mem...